Cara Yakhteh Tajhiz Azma

Cara Yakhteh Tajhiz Azma, a subsidiary of HITCO Holding, is a leading pharmaceutical manufacturing company dedicated to advancing innovative therapies and improving patient outcomes. Established in 2017, Cara Yakhteh Tajhiz Azma has focused its efforts on the CAR T cells project, assembling a dedicated research and development team of experts to pioneer this vital technology.

Cara Yakhteh Tajhiz Azma has successfully completed its research stages through continuous and dedicated effort, achieving breakthroughs in both producing engineered viruses and the final CAR T cells product. The company has also obtained the necessary approvals from relevant organizations to implement this technology for patients, marking a significant milestone in cancer treatment.

Committed to expanding its impact, Cara Yakhteh Tajhiz Azma is actively developing other types of CAR T cells therapies for the treatment of various hematologic malignancies and other types of cancers. In addition to its primary CAR T cells product targeting the cancer antigen CD19, Cara Yakhteh Tajhiz Azma is poised to revolutionize the pharmaceutical landscape. We invite the manager of Cara Yakhteh Tajhiz Azma to create a customized and exclusive company showcase and product listing on our platform.